Abstract The purpose of this randomized, double-blind parallel group study was to compare the safety, tolerability and acceptability of Easyhaler s and Turbuhaler s dry powder inhalers for the delivery of budesonide 800 mg day À1 in adult asthmatic patients who had already been treated with inhaled corticosteroids for at least 6 months prior to the study. Additionally the efficacy of the products was evaluated.The main objective was to evaluate the systemic safety of budesonide inhaled from Easyhaler s (Giona s Easyhaler s
INTRODUCTION
Airway in£ammation is considered to be the cause of the symptoms and physiological abnormalities of asthma and it should be the primary target of asthma treatment (1) . The in£ammation is characterised by the presence of in£ammatory cells such as eosinophils and neutrophils (2) .
Corticosteroids have been shown to suppress the airway in£ammation and bronchial hyperresponsiveness associated with asthma, and are now recommended as ¢rst-line therapy for the treatment of asthmatic patients (1) .
Clinically, the most important systemic adverse drug reactions (ADRs) of inhaled corticosteroids are hypothalamic^pituitary^adrenal (HPA) axis suppression (3^5), increased bone turnover (6) and impaired glucose and lipid metabolism (7) . However, these e¡ects are associated with high-dose therapy (41000 mg day À1 ) (8, 9) . At doses of up to 400 mg day À1 in children, and up to 800 mg day À1 in adults, inhaled corticosteroids have been shown to have minimal systemic e¡ects, irrespective of preparation (10) . The therapeutic goal should be to optimize asthma control with minimal systemic e¡ects or ADRs by adjusting the dose of inhaled corticosteroid according to individual requirements.
It is generally acknowledged that the inhaler is a key element in determining the e⁄cacy, adverse event pro¢le, and safety of asthma therapy (11) . Pressurized metered-dose inhalers (pMDIs) are currently the most common forms of delivery device for inhaled therapy in most European countries (12) . However, these devices are associated with a number of problems, notably di⁄culty in achieving the level of coordination necessary for correct dose delivery, leading to reduced effectiveness and poor compliance. Furthermore, most pMDIs contain ozone-depleting chloro£uorocarbons (CFCs) as propellants. Hence, these are being phased out to meet an imminent ban on the use of CFCs (12) . Non-CFC pMDIs are now available. These pMDIs have chlorine-free hydro£uoroalkane (HFA) as a propellant (13) .
In order to overcome these problems, breath-actuated powder inhalers were developed, and one of the ¢rst was Turbuhaler s (AstraZeneca, Sweden). Easyhaler s is a new generation breath-actuated multidose powder inhaler developed by Orion Pharma in Finland, and is currently available for the delivery of salbutamol and beclometasone dipropionate (BDP).
In the present study, primarily the safety, tolerability and acceptability of Easyhaler s and Turbuhaler s for the delivery of budesonide 800 mg day À1 were compared in adult asthmatic patients who had already been treated with inhaled corticosteroids. Additionally, the e⁄cacy of the products was evaluated. The main objective of the study was to evaluate the systemic safety of budesonide inhaled from Easyhaler s , as determined by serum and urine cortisol measurements. Secondary objectives were to compare the tolerability, acceptability and e⁄-cacy of the two devices. In addition, the bronchial in£am-mation and the e¡ect of budesonide on it was studied in the patients of two study centres using induced sputum method.
METHODS Patients
Non-smoking male and female asthma outpatients aged 18^70 years were recruited from 14 centres in Finland. All patients were required to have been diagnosed with bronchial asthma (ATS criteria) and to have used inhaled BDP or budesonide on a regular daily basis over at least the previous 6 months. For the 4 weeks prior to the study, they were also required to have inhaled BDP or budesonide at a dose level of 800^1000 mg day
À1
. In order to be included in the study, patients had to have a forced expiratory volume in 1sec (FEV 1 )460% of the predicted value before taking a bronchodilator, measured within 4 weeks before the beginning of the run-in period or on the ¢rst visit (14) .
Patients were excluded from the study if they had known hypersensitivity to either budesonide or lactose, or any exacerbation of asthma or respiratory infection during the previous 4 weeks. Ex-smokers could be included if they had stopped smoking at least 6 months prior to the study. Patients with a manifest heart condition (NYHA Class II^IV), severe hepatic or renal disease, inadequately controlled hyperthyroidism or diabetes mellitus (type I or II) were excluded from the study, as were women who were pregnant, breast-feeding or fertile and without reliable contraception. Patients were not allowed to have received oral corticosteroids or beta-blockers during the previous 4 weeks, nor could they have any regular treatment with anticholinergics, theophyllines, oral or inhaled cromoglycate, nedocromil, leukotriene antagonists, short-or long-acting antihistamines, or long-acting sympathomimetics during study entry. Patients who had previously participated in this study, or in any other clinical drug study within 8 weeks of this one, were also excluded. ,Orion Pharma, Finland) as rescue medication. If necessary, they could also take a1-week course of an oral corticosteroid (prednisolone 30^40 mg day À1 ) or one course of an antibiotic, but could be withdrawn from the study if they exceeded these limits. Home peak expiratory £ow (PEF) measurements were carried out using a standard MiniWright TM Peak Flow Meter (Clement Clarke International Ltd, England) before inhaling the drug and preferably, at least 6 h after any salbutamol inhalation.
Study design
After the run-in period and after the 6th,10th and14th study weeks, on the evening before the clinic visits, patients were asked to take the study drug (preferably at 8 p.m.) after they had emptied their bladder. They then started collecting all overnight urine for 10 h. No further corticosteroids were taken until completion of the follow-up visit the next morning. Use of salbutamol inhalation was to be avoided for 8 h before the follow-up visits.
Blood samples for measuring morning serum cortisol concentrations were taken after overnight fasting at the end of the run-in period and at the end of study weeks 6, 10 and 14, preferably at the same time at each visit (7^9 a.m.).
Sputum inductions for measuring eosinophils, neutrophils, macrophages, eosinophil cationic proteins (ECP) and myeloperoxidase (MPO) were performed in the patients of two study centers after run-in period and at the end of the study.
Compliance was determined by patient diary records of corticosteroid use, and return of both used and unused study drugs to the study centre at the end of the treatment period.
All study documents were reviewed and approved by the Ethics Committees of the participating hospitals. All patients were required to give written informed consent and the study was conducted according to the principles of the current revision of the Declaration of Helsinki (15) .
Outcome variables
The primary safety variable was the systemic bioactivity of budesonide, which was determined by measuring single morning (7^9 a.m.) serum cortisol (normal reference range190^700 nmol l
À1
) and urine free cortisol alone and corrected by creatinine excretion [urine cortisol/creatinine (UCC) ratio].
All adverse events, whether considered to be drug-related or not, were recorded in the patients' diaries, including type and severity (with a daily score of 0^3). Patients were speci¢cally asked to record and score any occurrence of hoarseness and sore throat, sum scores for which were calculated for the run-in period and every 4 weeks during treatment.During all follow-up visits, the presence of oropharyngeal candidiasis was determined by visual examination and, if there was evidence of infection, by oropharyngeal swabs. The number of courses of antimycotic treatment prescribed was also recorded.
Patients evaluated the acceptability of the devices at the last follow-up visit by use of a questionnaire on handling and ease of use, and a visual analogue scale (VAS) score for overall opinion of the devices (ranging from extremely bad to extremely good).
The primary e⁄cacy variables were mean morning and evening home PEF values, determined for the run-in period (weeks 1^2) and for weeks 3^4, 7^8 and 11^14. Secondary e⁄cacy variables included spirometry at the study site [FEV 1 and forced vital capacity (FVC)]; diurnal variability in PEF, expressed as [(highestÀlowest)/highest Â100% per day]; number of beta 2 -agonist inhalations during run-in and for each 4 -week treatment period thereafter; and severity sum scores for day-and nighttime asthma symptoms (dyspnoea, wheezing and cough, where 0=no symptoms, 1=mild, 2=moderate and 3=se-vere), calculated for the run-in period and every 4 weeks thereafter.
In addition, at two of the study centres, the severity of bronchial in£ammation was assessed by measuring eosinophils, neutrophils, ECP and MPO concentrations (mg l À1 in each case) in induced sputum after the run-in 
Statistical analysis
The main aim of the study was to evaluate the safety of inhaled budesonide 800 mg day
À1
. The ¢rst hypothesis was that there would be no signi¢cant change in morning serum cortisol in the Easyhaler s group from the end of the run-in period (baseline) to the end of the study. The second hypothesis was that there would be no signi¢cant di¡erence between treatment groups in morning serum cortisol during the study period, as assessed from individual measurements on follow-up visits. The secondary aim of the study was to collect evidence about the acceptability, tolerability and e⁄cacy of Giona s Easyhaler s compared to Pulmicort s Turbuhaler s . A twosided P-value of less than 5% was considered statistically signi¢cant.
For analyses concerning safety and tolerability, all available data were utilized. Conclusions concerning the safety and e⁄cacy of the treatments were based primarily on ITTanalyses.
Changes in morning serum cortisol, urine free cortisol and UCC ratio from baseline to the last visit were analysed using the Wilcoxon one-sample test. Betweentreatment comparisons in these variables were performed using analysis of covariance with baseline measured as a covariate.
All adverse events were classi¢ed by severity and by causal relationship to study treatment. The di¡erence in the number of oropharyngeal Candida infections was analysed only descriptively.
Improvement in morning and evening PEF was analysed separately for both treatment groups using an analysis of variance (ANOVA) model. Mean values for the 2-week run-in period and subsequent 4 -week treatment periods for each treatment were calculated.These values were analysed using repeated measurement analysis of covariance. The main interest lay on the comparison at treatment weeks 9^12, but also the overall treatment di¡erence, including the whole treatment period, was examined. Spirometric measurements were analysed accordingly, but instead of periodwise means actual values were used. Sum scores for asthma symptoms and sympathomimetic inhalations were analysed using the Mann^Whitney U-test.
Data of sputum induction are expressed as means. Some values for in£ammatory markers lay beneath lowest standard values. Results of comparisons between the two groups were analysed using Mann^Whitney U-test or the chi-squared test, as appropriate.Two-tailed P-values below 0?05 were considered to indicate signi¢cance.
The estimated sample size was based on the planned treatment randomization ratio (2:
RESULTS

Patients
A total of 161 patients were enrolled in the study, of whom 103 were randomised to the Giona s Easyhaler s group and 58 to the Pulmicort s Turbuhaler s group (Table 1). The distribution of female subjects di¡ered between the groups (58% in the Easyhaler s group and 74% in theTurbuhaler s group), which accounted for the observed di¡erences in terms of cortisol, PEF and spirometry values. In addition to asthma, a baseline disease was reported by 60% of patients in Easyhaler s group and 72% in Turbuhaler s group, the most common one being rhinitis. The most common baseline symptoms were headache, dysphonia and coughing and they occurred equally in both groups.
One hundred and forty-six patients completed the study: 91 in the Easyhaler s group and 55 in theTurbuhaler s group. Reasons for premature discontinuation in each group are shown inTable 2.
Compliance
According to the daily diaries of all patients who completed the study, the mean (SD) percentage of study drug usage was 98 (5) % in the Easyhaler s group and 98 (3) % in theTurbuhaler s group.
Safety
In the Easyhaler s group, morning serum cortisol values remained almost unchanged from baseline (end of the run-in period) until the end of the 12-week treatment period [ Fig. 2(a) ]. In theTurbuhaler s group, there was a slight decrease in morning serum cortisol values, but the di¡erence was not statistically signi¢cant between the groups. Five patients (two in the Easyhaler s group and three in theTurbuhaler s group) had one morning serum cortisol reading o190 nmol l
À1
, which was considered to be the lower limit of the normal reference value. In all except one patient (in theTurbuhaler s group) serum cortisol levels o190 nmol l À1 were associated with a course of an oral corticosteroid during the study.
Urine free cortisol values increased from baseline to the end of the treatment period in both treatment groups, but only in the Easyhaler s group was the di¡er-ence statistically signi¢cant (P=0?015 Fig. 2(b) ]. During the ¢rst month of treatment there were more adverse events in both treatment groups than during the third month. Fifty-two adverse events (52%) were considered to be possibly, probably, or de¢nitely related to study drug in the Easyhaler s group, and 31 (53%) were considered to be possibly, or probably drug-related in theTurbuhaler s group, and most were mild or moderate in nature (Table 3 ). In both treatment groups, mean scores (% of theoretical maximum) for hoarseness remained unchanged during the study and those for sore throat increased slightly.Only one patient (in the Easyhaler s group) discontinued the study due to an adverse event (coughing and worsening of asthma).Three serious adverse events (SAEs) occurred during the study: one hospitalization for haemorrhoid surgery in the Easyhaler s group; one hysterectomy for uterine myoma in the Turbuhaler s group; and one pregnancy ending in spontaneous abortion in theTurbuhaler s group.These were all considered to be unrelated to study drug by the investigators and by the sponsor, except for the spontaneous abortion, which was considered unlikely to be drug-related.
During treatment, the occurrence of oropharyngeal candidiasis (8/103 in the Easyhaler s group and 4/58 in the Turbuhaler s group), and the number of courses of antimycotics prescribed (7/103 and 4/58 in each group, respectively) were similar in both groups.
Acceptability
In four out of 10 questions, a majority of the patients (450%) rated Easyhaler s superior to Turbuhaler s , although more patients found Turbuhaler s 'handier to carry' (Fig. 3) . In particular, with Easyhaler s most patients found it easier to know when the drug had been received and how much drug was left. When asked (155) 817 (57) *Values from the measurements done at visit 2 (end of run-in period). 
E⁄cacy
There were no statistically signi¢cant di¡erences in mean morning PEF values between the treatment groups, with no signi¢cant changes from baseline to the end of treatment (Table 4 ).The overall adjusted treatment di¡erence was 1?5 lmin À1 (95% CI from À5?6 to 8?5).The results of mean evening PEF values were in accordance with the morning PEF results (Table 4) .
Both FEV 1 and FVCvalues remained almost unchanged during the study in both treatment groups, with no signi¢cant di¡erences between the groups (Table 4) .
The use of additional inhaled salbutamol during the run-in and treatment periods was low and similar in both groups.
The incidence of daytime asthma symptoms (dyspnoea, wheezing and cough) was similar in each group and remained more or less unchanged throughout the study. Night-time asthma symptoms also remained similar in the Easyhaler s group but increased slightly from run-in to treatment weeks 9^12 for all three symptoms A total of 21 patients underwent sputum induction for analysis of in£ammatory markers. Most patients (13/21) had low amount of sputum eosinophils (scale 0^1, less than 5%) at baseline. Sputum eosinophils in both groups decreased signi¢cantly during the budesonide treatment (P=0?02) (Fig. 4 ). There were no signi¢cant changes in ECP and MPO values during the study and no di¡erence between treatments studied.
DISCUSSION
It has previously been reported that most of the bene¢ts of inhaled corticosteroids are achieved within 3 months of starting therapy (18) . The duration of treatment period in this study was selected not only because of the pharmacodynamics of budesonide, but also to obtain a reliable picture of the safety, tolerability and acceptability of the treatments studied. Pulmicort (19) and that total plasma creatinine is an accurate measure of total striated muscle mass (20) . Also oestrogens can have in£uence on corticosteroid binding globulin and cortisol concentration (21) .Thus, di¡erence in female/male distribution can have in£uence both on creatinine and cortisol concentration and also cortisol/creatinine ratio, which may explain the di¡erence at baseline found in the present study.
Most multicentre studies have used single morning serum cortisol measurements as a practical means of assessing potential HPA axis suppression (22, 23) . However, this method is relatively insensitive, since there is marked diurnal variation in serum or plasma cortisol levels. Therefore, in this study overnight (10 h) urinary unbound cortisol was also determined, since it has been shown to be a more sensitive measure of HPA axis function (24, 25) . Overnight collection of urine for determination of urine free cortisol is also simple to carry out and has been reported to be as sensitive as 24 -h collection, particularly when corrected for creatinine (24) .
The results showed that mean morning serum cortisol values remained relatively unchanged in the Easyhaler s group and, although there was some decrease in the Turbuhaler s group, mean values were above 400 nmol l À1 in both groups after the run-in period and after12 weeks of treatment. In addition, urine free cortisol values and UCC ratios increased in both groups during treatment and the changes from baseline were statistically signi¢cant in the Easyhaler s group. Other safety parameters did not di¡er signi¢cantly between the treatment groups. Most of the adverse events considered to have any possible relationship to study drug were mild or moderate in nature and there were no SAEs considered to be related to study drug.
There were no signi¢cant di¡erences between the treatment groups in any of the e⁄cacy variables, which remained largely unchanged during the study. This was expected because all patients had used inhaled corticosteroids (800^1000 mg day À1 of BDP or budesonide) for at least 6 months prior to the study.
The analysis of induced sputum has become an accepted method for assessing the degree of in£ammation and has been reported to be useful in the evaluation of asthma severity and the e¡ect of inhaled corticosteroid treatment (26^28). Recent studies have demonstrated a correlation between the markers of in£ammation used, ECP and MPO, and the clinical data (26^30).This method also has the advantage of being a non-invasive technique. Markers of in£ammation in induced sputum varied between patients in both treatment groups. In most patients with asthma previously treated with inhaled steroids, sputum eosinophils are low (30) . However, under controlled budesonide treatment eosinophils decreased signi¢cantly. Both inhalers studied had equal anti-in£ammatory e¡ects also on the basis of sputum results.
Response to the acceptability questionnaire showed that the majority of patients rated 
